| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Chemoprevention [M. S. L., M. A. A., C. W. P., A. B. R., M. B. S.] and Biometry Branch [C. C. B.], National Cancer Institute, NIH, Bethesda, Maryland 20892; Department of Veterinary Pathology, Armed Forces Institute of Pathology, Washington DC 20306 [M. V. S.]; and Science Applications International Corporation-Frederick, Frederick, Maryland 21702 [M. R. A., D. M. G., M. W. S., D. L. L., C. L. D.]
We evaluated the ability of dietary N-(4-hydroxyphenyl)retinamide; 1
,25-dihydroxy-16-ene-23-yne-26,27-hexafluorocholecalciferol (Ro24-5531); and tamoxifen to inhibit the development of androgen-promoted carcinomas of the accessory sex organs of male Lobund-Wistar rats. Invasive carcinomas of the seminal vesicle (SV) and anterior prostate (AP) were induced in Lobund-Wistar rats with three different combinations of initiator [N-nitroso-N-methylurea (NMU)] and promoter [testosterone propionate (TP)]: (a) high-dose NMU (30 mg/kg) + high-dose TP (20 mg via implant every 2 months); (b) high-dose NMU + low-dose TP (10 mg implanted every 2 months); or (c) low-dose NMU (15 mg/kg) + low-dose TP. During the period of TP administration, rats were fed a diet supplemented with either N-(4-hydroxyphenyl)retinamide (1 or 2 mmol/kg diet), Ro24-5531 (1.25 or 2.5 nmol/kg diet), tamoxifen (0.5 or 5 mg/kg diet), or vehicle alone. After sacrifice at 8.5 or 11 months, the prostate-seminal vesicle complex from each rat was processed in toto and histologically staged as to the extent of tumor involvement. In animals given low-dose TP, all three agents were significantly effective at reducing the incidence of invasive carcinomas of the SV and, to a lesser degree, the AP. Of the three agents, tamoxifen given in high dose (5 mg/kg) had the strongest activity, reducing the occurrence of invasive SV carcinomas from 72–83% in controls to 6% (P = 0.0001) and the occurrence of invasive AP carcinomas from 50–72% to 18–22% (P < 0.05).
1 These authors are all considered first authors on the work described herein.
2 To whom requests for reprints should be addressed, at Department of Pathology, Box B-216, University of Colorado Medical Center, Denver, CO 80262.
3 Present address: Stine-Haskell Research Center, DuPont Merck Pharmaceutical Company, Newark, DE 19714.
4 Present address: Department of Pharmacology, Dartmouth Medical School, Hanover, NH 03755.
Received 6/19/95. Accepted 9/26/95.
This article has been cited by other articles:
|
|
 |
|
  S. Masuda and G. Jones Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pollard and M. A. Suckow Hormone-Refractory Prostate Cancer in the Lobund-Wistar Rat Experimental Biology and Medicine, September 1, 2005; 230(8): 520 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Beer, A. Myrthue, M. Garzotto, M. F. O'Hara, R. Chin, B. A. Lowe, M. A. Montalto, C. L. Corless, and W. D. Henner Randomized Study of High-Dose Pulse Calcitriol or Placebo prior to Radical Prostatectomy Cancer Epidemiol. Biomarkers Prev., December 1, 2004; 13(12): 2225 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Giordano, A. U. Buzdar, and G. N. Hortobagyi Breast Cancer in Men Ann Intern Med, August 19, 2003; 139(4): 305 - 305. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Song, S. C. Cornelius, and D. Danielpour Development and Characterization of DP-153, a Nontumorigenic Prostatic Cell Line That Undergoes Malignant Transformation by Expression of Dominant-negative Transforming Growth Factor {beta} Receptor Type II Cancer Res., August 1, 2003; 63(15): 4358 - 4367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rodriguez, M. L. McCullough, A. M. Mondul, E. J. Jacobs, D. Fakhrabadi-Shokoohi, E. L. Giovannucci, M. J. Thun, and E. E. Calle Calcium, Dairy Products, and Risk of Prostate Cancer in a Prospective Cohort of United States Men Cancer Epidemiol. Biomarkers Prev., July 1, 2003; 12(7): 597 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Peehl, A. V. Krishnan, and D. Feldman Pathways Mediating the Growth-Inhibitory Actions of Vitamin D in Prostate Cancer J. Nutr., July 1, 2003; 133(7): 2461S - 2469. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Christov, R. C. Moon, D. D. Lantvit, C. W. Boone, V. E. Steele, R. A. Lubet, G. J. Kelloff, and J. M. Pezzuto 9-cis-Retinoic Acid but Not 4-(Hydroxyphenyl)retinamide Inhibits Prostate Intraepithelial Neoplasia in Noble Rats Cancer Res., September 15, 2002; 62(18): 5178 - 5182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Perez-Stable, G. G. Schwartz, A. Farinas, M. Finegold, L. Binderup, G. A. Howard, and B. A. Roos The G{gamma}/T-15 Transgenic Mouse Model of Androgen-independent Prostate Cancer: Target Cells of Carcinogenesis and the Effect of the Vitamin D Analogue EB 1089 Cancer Epidemiol. Biomarkers Prev., June 1, 2002; 11(6): 555 - 563. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M Chan, M. J Stampfer, J. Ma, P. H Gann, J M. Gaziano, and E. L Giovannucci Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study Am. J. Clinical Nutrition, October 1, 2001; 74(4): 549 - 554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. W. Kensler, P. M. Dolan, S. J. Gange, J.-K. Lee, Q. Wang, and G. H. Posner Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis Carcinogenesis, July 1, 2000; 21(7): 1341 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Sporn and N. Suh Chemoprevention of cancer Carcinogenesis, March 1, 2000; 21(3): 525 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Prevention of Cancer in the Next Millennium: Report of the Chemoprevention Working Group to the American Association for Cancer Research Cancer Res., October 1, 1999; 59(19): 4743 - 4758. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lopez-Otin and E. P. Diamandis Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features Endocr. Rev., August 1, 1998; 19(4): 365 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. K. Hong and M. B. Sporn Recent Advances in Chemoprevention of Cancer Science, November 7, 1997; 278(5340): 1073 - 1077. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
